Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Trading Down 13.3 %

Eagle Pharmaceuticals stock opened at $0.65 on Friday. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.81. The stock has a fifty day moving average of $0.73 and a 200 day moving average of $3.17.

Institutional Trading of Eagle Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC bought a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at approximately $971,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Eagle Pharmaceuticals in the third quarter worth $453,000. Jane Street Group LLC bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at $96,000. Cubist Systematic Strategies LLC purchased a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at $145,000. Finally, AIGH Capital Management LLC boosted its holdings in Eagle Pharmaceuticals by 2.1% in the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after buying an additional 25,000 shares during the period. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.